# Immune-Related Adverse Events in a Patient With Burkitt's Lymphoma During PD-1 Immune Consolidation Therapy: A Case Report

## TL;DR

A patient with Burkitt's lymphoma experienced gastrointestinal issues during PD-1 therapy, which improved with vedolizumab, offering insights into managing immune-related side effects in lymphoma treatment.

## Contribution

This case report highlights the use of vedolizumab as an effective adjunct to PD-1 therapy in managing immune-related adverse events in non-Hodgkin's lymphoma.

## Key findings

- A patient with Burkitt's lymphoma experienced upper gastrointestinal adverse events during PD-1 therapy.
- Adjunctive vedolizumab administration improved the patient's symptoms.
- The case suggests potential for PD-1 inhibitors in non-Hodgkin's lymphoma with proper management of side effects.

## Abstract

A patient with Burkitt's lymphoma developed upper gastrointestinal adverse events during immune consolidation therapy following chemotherapy combined with autologous stem cell transplantation. Subsequent administration of vedolizumab as adjunctive therapy resulted in improvement of the patient's symptoms. This case is expected to provide a reference for the expanded application of PD-1 inhibitors in non-Hodgkin's lymphoma.